SCHEMBL6839385

SCHEMBL6839385

CCOP(=O)(OCC)c1ccccc1Br

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.53
KMT2A Q03164 3/20 0.53
POLB P06746 2/20 0.44
NPSR1 Q6W5P4 2/20 0.43
KCNH2 Q12809 1/20 0.42
CA12 O43570 1/20 0.41
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
CA4 P22748 1/20 0.41
CA5A P35218 1/20 0.41
CA7 P43166 1/20 0.41
CA9 Q16790 1/20 0.41
CA5B Q9Y2D0 1/20 0.41
ALDH1A1 P00352 2/20 0.41
ACHE P22303 1/20 0.40
GAA P10253 2/20 0.39
KDM4E B2RXH2 2/20 0.39
HPGD P15428 2/20 0.39
NR1I2 O75469 1/20 0.39
HSD17B10 Q99714 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18486629 0.86 MEN1 (0.61) MEN1KMT2APOLBNPSR1KCNH2
SCHEMBL21319337 0.83 NPSR1 (0.42) MEN1KMT2APOLBNPSR1KCNH2
SCHEMBL16974734 0.79 MEN1 (0.44) MEN1KMT2APOLBNPSR1KCNH2
SCHEMBL31482562 0.78 KMT2A (0.54) MEN1KMT2APOLBNPSR1KCNH2
SCHEMBL3890445 0.78 KMT2A (0.54) MEN1KMT2APOLBNPSR1KCNH2
SCHEMBL4455340 0.78 MEN1 (0.54) MEN1KMT2APOLBNPSR1KCNH2
SCHEMBL9177686 0.78 MEN1 (0.50) MEN1KMT2APOLBNPSR1KCNH2
SCHEMBL21319400 0.78 CA1 (0.37) MEN1KMT2APOLBCA12CA1
SCHEMBL780087 0.77 MEN1 (0.53) MEN1KMT2APOLBNPSR1KCNH2
SCHEMBL641441 0.77 MEN1 (0.53) MEN1KMT2APOLBNPSR1KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116854631-B 4-Aryl-2-pyridone compound and preparation method thereof 安徽中医药大学 2025-04-15 CN claimed
CN-116854631-A 4-aryl-2-pyridone compound and preparation method thereof 安徽中医药大学 2023-10-10 CN claimed
US-20040138487-A1 Bisphospholane ligands with metals for hydrogenation catalysts for enantiomorphs HOGE GARRETT STEWART 2004-07-15 US claimed
US-20030073868-A1 Non-C2-symmetric bisphosphine ligands as catalysts for asymmetric hydrogenation WARNER-LAMBERT COMPANY 2003-04-17 US claimed
US-20020143214-A1 Synthesis of non-C2-symmetric bisphosphine ligands as catalysts for asymmetric hydrogenation HOGE GARRETT STEWART (US) 2002-10-03 US claimed
CN-116854631-B 4-Aryl-2-pyridone compound and preparation method thereof 安徽中医药大学 2025-04-15 CN disclosed
CN-116854631-A 4-aryl-2-pyridone compound and preparation method thereof 安徽中医药大学 2023-10-10 CN disclosed
US-7414156-B2 Non-C2-symmetric bisphosphine ligands as catalysts for asymmetric hydrogenation WARNER LAMBERT CO. (US) 2008-08-19 US disclosed
US-7414156-B2 Non-C2-symmetric bisphosphine ligands as catalysts for asymmetric hydrogenation WARNER LAMBERT CO. (US) 2008-08-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020143214-A1 Synthesis of non-C2-symmetric bisphosphine ligands as catalysts for asymmetric hydrogenation PHOSPHO1, PPIP5K2, PFKFB2 MEN1 94/4885KMT2A 3175/4885POLB 2077/4885
US-20030073868-A1 Non-C2-symmetric bisphosphine ligands as catalysts for asymmetric hydrogenation PHOSPHO1, PPIP5K2, DNM2 MEN1 68/4885KMT2A 2844/4885POLB 1963/4885
US-20040138487-A1 Bisphospholane ligands with metals for hydrogenation catalysts for enantiomorphs BPGM, PHOSPHO1, PPIP5K2 MEN1 190/4885KMT2A 3539/4885POLB 1970/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.